دورية
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFRmutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
| العنوان: | Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFRmutations (BELIEF): an international, multicentre, single-arm, phase 2 trial |
|---|---|
| المؤلفون: | Rosell, Rafael, Dafni, Urania, Felip, Enriqueta, Curioni-Fontecedro, Alessandra, Gautschi, Oliver, Peters, Solange, Massutí, Bartomeu, Palmero, Ramon, Aix, Santiago Ponce, Carcereny, Enric, Früh, Martin, Pless, Miklos, Popat, Sanjay, Kotsakis, Athanasios, Cuffe, Sinead, Bidoli, Paolo, Favaretto, Adolfo, Froesch, Patrizia, Reguart, Noemí, Puente, Javier, Coate, Linda, Barlesi, Fabrice, Rauch, Daniel, Thomas, Michael, Camps, Carlos, Gómez-Codina, Jose, Majem, Margarita, Porta, Rut, Shah, Riyaz, Hanrahan, Emer, Kammler, Roswitha, Ruepp, Barbara, Rabaglio, Manuela, Kassapian, Marie, Karachaliou, Niki, Tam, Rachel, Shames, David S, Molina-Vila, Miguel A, Stahel, Rolf A |
| المصدر: | The Lancet Respiratory Medicine; May 2017, Vol. 5 Issue: 5 p435-444, 10p |
| مستخلص: | The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations. The coexistence of the T790M resistance mutation with another EGFRmutation in treatment-naive patients has been associated with a shorter progression-free survival to EGFR inhibition than in the absence of the T790M mutation. To test this hypothesis clinically, we developed a proof-of-concept study, in which patients with EGFR-mutant NSCLC were treated with the combination of erlotinib and bevacizumab, stratified by the presence of the pretreatment T790M mutation. |
| قاعدة البيانات: | Supplemental Index |
| تدمد: | 22132600 22132619 |
|---|---|
| DOI: | 10.1016/S2213-2600(17)30129-7 |